Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

 
• By Joseph Haas
  
Coronavirus with cardio lines, cellular designs and lungs
Merck & Co. likes therapeutic potential of OncoImmune's recombinant fusion protein
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business